The Prevalence of Hepatitis C Virus Genotype 1A in Japan and Correlation Between the Mutations in the NS5A Region With Response to Pegylated-Interferon-Alpha 2B Plus Ribavirin Combination Therapy

被引：0
|
作者：
Hayashi, Kazuhiko
Katano, Yoshiaki
Ishigami, Masatoshi
Nakano, Isao
Itoh, Akihiro
Hirooka, Yoshiki
Goto, Hidemi
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
T1986
引用
收藏
页码：S843 / S843
页数：1
相关论文
共 50 条
  • [31] Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy
    Hayashi, Kazuhiko
    Katano, Yoshiaki
    Honda, Takashi
    Ishigami, Masatoshi
    Itoh, Akihiro
    Hirooka, Yoshiki
    Ishikawa, Tetsuya
    Nakano, Isao
    Yoshioka, Kentaro
    Toyoda, Hidenori
    Kumada, Takashi
    Goto, Hidemi
    LIVER INTERNATIONAL, 2011, 31 (09) : 1359 - 1365
  • [32] Mutations in the Interferon Sensitivity-Determining Region of Hepatitis C Virus Genotype 2a Correlate With Response to Pegylated-Interferon-Alpha 2a Monotherapy
    Hayashi, Kazuhiko
    Katano, Yoshiaki
    Honda, Takashi
    Ishigami, Masatoshi
    Itoh, Akihiro
    Hirooka, Yoshiki
    Nakano, Isao
    Urano, Fumihiro
    Yoshioka, Kentaro
    Toyoda, Hidenori
    Kumada, Takashi
    Goto, Hidemi
    JOURNAL OF MEDICAL VIROLOGY, 2009, 81 (03) : 459 - 466
  • [33] Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
    Hill, Deanna D.
    Kramer, Jennifer R.
    Chaffin, Kassie R.
    Mast, T. Christopher
    Robertson, Michael N.
    Kanwal, Fasiha
    Haber, Barbara A.
    ANNALS OF HEPATOLOGY, 2023, 28 (02)
  • [34] Mutagenic effect of ribavirin in NS5A and NS5B regions and response to interferon/ribavirin combination therapy in patients with chronic hepatitis C
    Asahina, Y
    Izumi, N
    Ueda, K
    Inoue, K
    Nishimura, Y
    Tsuchiya, K
    Hamano, K
    Itakura, J
    Noguchi, O
    Uchihara, M
    Miyake, S
    Enomoto, N
    Watanabe, M
    GASTROENTEROLOGY, 2003, 124 (04) : A777 - A777
  • [35] Discovering Relationship between Hepatitis C Virus NS5A Protein and Interferon/Ribavirin Therapy
    Kawasaki, Saori
    Ho, Tu Bao
    Kanda, Tatsuo
    Yokosuka, Osamu
    Takabayashi, Katsuhiro
    Le, Nhan
    KNOWLEDGE, INFORMATION, AND CREATIVITY SUPPORT SYSTEMS, 2011, 6746 : 79 - +
  • [36] Mutational diversity of NS5A and NS3 during triple therapy (telaprevir, pegylated-interferon-α 2b and ribavirin) for genotype 1b chronic hepatitis C: The Kobe Hepatitis Therapeutic Group
    Bai, Fugui
    Yano, Yoshihiko
    Kim, Soo-Ryang
    Seo, Yasushi
    Miki, Akira
    Saito, Masaya
    Hirano, Hirotaka
    Momose, Kenji
    Minami, Akihiro
    Hatazawa, Yuri
    Hayakumo, Takanobu
    Widasari, Dewiyani Indah
    Rinonce, Hanggoro Tri
    Sugano, Masahiko
    Tani, Satoshi
    Yoon, Seitetsu
    Imoto, Susumu
    Azuma, Takeshi
    Hotta, Hak
    Hayashi, Yoshitake
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 33 (06) : 1652 - 1656
  • [37] Naturally occurring drug resitance substitutions in the NS5A and NS5B regions in Hepatitis C virus genotype 2 and response to sofosbuvir plus ribavirin therapy
    Hayashi, K.
    Ishigami, M.
    Ishizu, Y.
    Kazuya, T.
    Honda, T.
    Hirooka, Y.
    Goto, H.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S297 - S297
  • [38] Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy
    El-Shamy, Ahmed
    Shoji, Ikuo
    Saito, Takafumi
    Watanabe, Hisayoshi
    Ide, Yoshi-Hiro
    Deng, Lin
    Kawata, Sumio
    Hotta, Hak
    MICROBIOLOGY AND IMMUNOLOGY, 2011, 55 (06) : 418 - 426
  • [39] A significant association of the substitution in position 2209 of NS5A of hepatitis C virus 1b infection and the response to standard, consensus, or pegylated interferon plus ribavirin therapy.
    Moriguchi, H
    Uemura, T
    Sato, C
    HEPATOLOGY, 2005, 42 (04) : 689A - 689A
  • [40] Cost effectiveness of pegylated interferon alpha 2b and ribavirin combination in chronic hepatitis C
    Poynard, T
    GUT, 2003, 52 (10) : 1532 - 1532
12345